Title:
アリピプラゾールプロドラッグ組成物
Document Type and Number:
Japanese Patent JP6826167
Kind Code:
B2
Abstract:
To address a challenge of patient compliance during a 14-day lead-in period.SOLUTION: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume-based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilization of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for producing a lead-in formulation. Also described are methods of treatment using the composition.SELECTED DRAWING: Figure 9
Inventors:
Cresswell, Philip
Hicky, Magari
Riversedge, Eleinu
Mansart, Devud
Palmieri, Michael, Jr.
Packet, Sarah Montminy
Perkin, christopher
Smith, Greg
Steinberg, Brian
Turncliffe, Ryan
Zeidan, Tarek
Cash, Esampie.
Hard, Margie.
Hicky, Magari
Riversedge, Eleinu
Mansart, Devud
Palmieri, Michael, Jr.
Packet, Sarah Montminy
Perkin, christopher
Smith, Greg
Steinberg, Brian
Turncliffe, Ryan
Zeidan, Tarek
Cash, Esampie.
Hard, Margie.
Application Number:
JP2019145176A
Publication Date:
February 03, 2021
Filing Date:
August 07, 2019
Export Citation:
Assignee:
Arcames Pharma Ireland Limited
International Classes:
A61K31/496; A61K9/10; A61K9/14; A61K47/26; A61K47/38
Domestic Patent References:
| JP2013136621A | ||||
| JP2014508176A | ||||
| JP2005508939A |
Attorney, Agent or Firm:
Akio Miyazaki
Masaaki Ogata
Masaaki Ogata